Search results for "Dication"

showing 10 items of 733 documents

β-Blockers in Patients With Intermittent Claudication and Arterial Hypertension

2011

The use of β-receptor blockers in peripheral arterial disease is controversial for their impact on vasomotor tone. The β-blocker nebivolol possesses vasodilating, endothelium-dependent, NO-releasing properties that might be beneficial in peripheral arterial disease. The aim of the study was to evaluate the effects and tolerability of nebivolol in comparison with metoprolol in these patients. A total of 128 patients with intermittent claudication and essential hypertension were included and double-blind randomized to receive 5 mg of nebivolol (N=65) or 95 mg of metoprolol (N=63) once daily. End points were changes in ankle-brachial index, initial and absolute claudication distance, endothel…

Malemedicine.medical_specialtyBrachial ArteryAdrenergic beta-AntagonistsArterial Occlusive DiseasesBlood PressureEssential hypertensionNebivololDouble-Blind MethodSurveys and QuestionnairesInternal medicinemedicine.arteryInternal MedicinemedicineHumansAnkle Brachial IndexBenzopyransBrachial arteryAntihypertensive AgentsMetoprololbusiness.industryIntermittent Claudicationmedicine.diseaseNebivololIntermittent claudicationTreatment OutcomeBlood pressureTolerabilityEthanolaminesAnesthesiaHypertensionQuality of LifeCardiologyFemalemedicine.symptomClaudicationbusinessMetoprololmedicine.drugHypertension
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain

2020

Background: Cardiovascular prevention and rehabilitation programmes (CVPRP) are an established model of care designed to improve risk factor management. They have been successfully implemented in a variety of settings, in patients with coronary heart disease (CHD). Objective: To assess the long term impact of a nurse-coordinated, multidisciplinary, CVPRP in patients with CHD in the reduction of lipid profile and medication prescription in clinical practice. Methods: The study used an analytical, experimental, population based, prospective and longitudinal design. In Spain, the study was conducted in the Valencian Community, including two randomized hospitals. Coronary patients were prospec…

Malemedicine.medical_specialtyCardiotonic AgentsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentNurse's RoleMedication prescriptionCardiovascular preventionIntervention (counseling)HumansImmunology and AllergyMedicineLongitudinal StudiesProspective StudiesMedical prescriptionHealth policyAgedRehabilitationmedicine.diagnostic_testbusiness.industryMiddle AgedLipidsCoronary heart diseaseEuropePrimary PreventionCardiovascular DiseasesSpainEmergency medicineFemaleDiet HealthyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profileRisk Reduction BehaviorEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program

2014

Summary Background Depressive symptoms have detrimental effects on quality of life and mortality. Poor adherence to a treatment regimen is a potential mechanism for the increased risk of adverse medical events associated with depression. Regarding oral anticoagulation with vitamin K antagonists, adherence is crucial for the outcome. Little is known about the clinical relevance of current depressiveness for anticoagulation treatment. Objectives To examine the impact of current depressiveness on anticoagulation treatment in regular medical care. Patients/Methods We examined the association between clinically significant depressiveness as assessed by the Patient Health Questionnaire-2 ≥ 2 (PHQ…

Malemedicine.medical_specialtyCross-sectional studyAdministration OralHealth literacyMedication AdherenceCohort StudiesPatient satisfactionQuality of lifeAmbulatory careSurveys and QuestionnairesInternal medicineAmbulatory CarePrevalenceHumansMedicineClinical significanceInternational Normalized RatioDepression (differential diagnoses)AgedDepressionbusiness.industryAnticoagulantsHematologyMiddle AgedCross-Sectional StudiesTreatment OutcomePatient SatisfactionMultivariate AnalysisPhenprocoumonQuality of LifePhysical therapyFemalebusinessCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Patient Expectations in the Treatment of Painful Diabetic Polyneuropathy: Results from a Non-Interventional Study

2014

Objective Pain control is the main objective when treating patients with painful diabetic peripheral neuropathic pain (DPNP). However, DPNP is associated with further substantial patient burden that often is not appropriately addressed. Our study identified patients' needs and asked patients what they expected from DPNP treatment. Methods Baseline data were collected in a German prospective, non-interventional study in patients with DPNP starting or switching pain medication at the discretion of the investigator. DPNP severity was evaluated using Brief Pain Inventory (BPI) and Clinician/Patient Global Impression-Severity (CGI-S/PGI-S). Primary objective of this study was to evaluate for whi…

Malemedicine.medical_specialtyDiabetic neuropathyPain medicationCohort StudiesDiabetic NeuropathiesDiabetic polyneuropathyActivities of Daily LivingHumansMedicineIn patientProspective StudiesMobility LimitationBrief Pain InventoryAgedbusiness.industryPatient PreferenceGeneral MedicineMiddle Agedmedicine.diseasehumanitiesConfidence intervalAnesthesiology and Pain MedicineMoodPatient SatisfactionNon interventionalQuality of LifePhysical therapyFemaleNeurology (clinical)businessAttitude to HealthNeeds AssessmentPain Medicine
researchProduct

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction…

2019

Background Physicians’ adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. In this analysis we assessed the longer-term association of physicians’ adherence with clinical outcomes, including mortality and unplanned hospitalisations, at 18-month follow-up of the QUALIFY registry (Clinical trial registration ISRCTN87465420) Method and results Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0…

Malemedicine.medical_specialtyDoseMedication Therapy ManagementHeart failureOutcomes030204 cardiovascular system & hematologyGuidelinesMedication03 medical and health sciences0302 clinical medicineDosageInternal medicineMedication therapy managementOutcome Assessment Health CareOutpatientsmedicineHumansRegistriesPractice Patterns Physicians'Heart FailureEjection fractionGuideline adherencebusiness.industryCardiovascular AgentsStroke VolumeStroke volumeMiddle Agedmedicine.diseaseQuality ImprovementConfidence intervalClinical trialHospitalizationAdherenceHeart failureCardiovascular agentAmbulatoryPractice Guidelines as TopicObservational studyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean journal of heart failure
researchProduct

ANTI-ARRHYTHMIC EFFECT OF DEHYDROBENZPERIDOL IN DOGS

1971

SUMMARY The anti-arrhythmic activity of dehydrobenzperidol (DBP) was studied during halothane anaesthesia in dogs. Arrhythmias were provoked by single intravenous injections of catecholamines. Two groups of dogs were studied. One received norepinephrine and the odier epinephrine. The dose just sufficient to initiate arrirythmias was defined as the “threshold”. Electrocardiogram, blood pressure and heart rate were monitored. The principal findings were:— 1  The dog heart was “sensitized” to epinephrine and norepinephrine by halothane. 2  DBP did have an anti-arrhydimic action. A dose of 0.150 mg/kg roughly doubled the “threshold”. 3  DBP had significant alpha-adrenergic blocking properties. …

Malemedicine.medical_specialtyEpinephrineBlood PressureNorepinephrine (medication)ElectrocardiographyNorepinephrineDogsHeart RateInternal medicineHeart ratemedicineAnimalsAnti arrhythmiccardiovascular diseasesbusiness.industryBenperidolRespirationHalothane anaesthesiaHeartGeneral MedicineDehydrobenzperidolAnesthesiology and Pain MedicineEndocrinologyEpinephrineFemaleDog heartHalothaneHalothanebusinesscirculatory and respiratory physiologymedicine.drugActa Anaesthesiologica Scandinavica
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis

2018

Background Temporal artery biopsy (TAB) is a surgical procedure with a low positive yield. The purpose of this study is to determine which variables are the most important in the giant cell arteritis (GCA) diagnosis. The objective of this evaluation is to improve the percentage of positive temporal artery biopsy and if possible, avoid the biopsy in some cases. Material and Methods A retrospective clinical study consisted of 90 patients who had undergone TAB at the Río Hortega Hospital (Spain) from January 2009 to December 2016. Clinical findings, erythrocyte sedimentation rates (ESR) and other laboratory parameters, American College of Rheumatology (ACR) criteria for GCA score and biopsy re…

Malemedicine.medical_specialtyGiant Cell ArteritisLogistic regression03 medical and health sciences0302 clinical medicineInternal medicineBiopsymedicineHumans030212 general & internal medicineArteritisskin and connective tissue diseasesGeneral DentistryAgedRetrospective Studies030203 arthritis & rheumatologyOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryResearchHeadacheRetrospective cohort studyTemporomandibular Joint Disordersmedicine.disease:CIENCIAS MÉDICAS [UNESCO]RheumatologyJaw claudicationGiant cell arteritismedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemalebusinessArteryMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct